Ovid Therapeutics (OVID) Enterprise Value (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Enterprise Value came in at -$155.5 million in Q1 2026, down 281.32% YoY from $85.8 million in Q1 2025, and down 123.34% on a QoQ basis from -$69.6 million in Q4 2025.
Ovid Therapeutics (OVID) Enterprise Value (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Enterprise Value data on file, last reported at -$155.5 million in Q1 2026.
- Quarterly Enterprise Value fell 281.32% year-over-year to -$155.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$155.5 million (down 281.32% YoY) and the FY2025 annual result came in at -$69.6 million, down 32.5% from the prior year.
- Enterprise Value eased to -$155.5 million in Q1 2026, from -$69.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$25.5 million in Q3 2025 to a low of -$168.6 million in Q1 2022.
- A 5-year average of -$94.0 million and a median of -$88.9 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value surged 58.19% — and 2026, when it sank 281.32%.
- Tracing OVID's Enterprise Value over 5 years: stood at -$126.1 million in 2022, then climbed by 18.25% to -$103.1 million in 2023, then surged by 49.04% to -$52.6 million in 2024, then sank by 32.5% to -$69.6 million in 2025, then slumped by 123.34% to -$155.5 million in 2026.
- The last three Enterprise Value figures came in at -$155.5 million (Q1 2026), -$69.6 million (Q4 2025), and -$25.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -155.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155.52 Mn |
| Dec 31, 2025 | -69.64 Mn |
| Sep 30, 2025 | -25.48 Mn |
| Jun 30, 2025 | -38.35 Mn |
| Mar 31, 2025 | -40.79 Mn |
| Dec 31, 2024 | -52.55 Mn |
| Sep 30, 2024 | -60.93 Mn |
| Jun 30, 2024 | -76.97 Mn |
| Mar 31, 2024 | -88.94 Mn |
| Dec 31, 2023 | -103.13 Mn |
| Sep 30, 2023 | -87.07 Mn |
| Jun 30, 2023 | -96.52 Mn |
| Mar 31, 2023 | -117.72 Mn |
| Dec 31, 2022 | -126.15 Mn |
| Sep 30, 2022 | -137.86 Mn |
| Jun 30, 2022 | -152.37 Mn |
| Mar 31, 2022 | -168.60 Mn |
| Dec 31, 2021 | -187.80 Mn |
| Sep 30, 2021 | -201.80 Mn |
| Jun 30, 2021 | -212.20 Mn |